References
- ACDP (2011). Minutes from the 1st meeting of the ACDP Transmissible Spongiform Encephalopathy Risk Assessment Subgroup. July 2011. Available at: http://www.dh.gov.uk/ab/ACDP/TSEguidance/DH_125868, accessed 15 November 2011.
- ACDP (2012a). Minutes from the 2nd meeting of the ACDP Transmissible Spongiform Encephalopathy Risk Assessment Subgroup. Available at http://transparency.dh.gov.uk/2012/08/13/tse-subgroup-may-2012, accessed 11 February 2013.
- ACDP (2012b). Advisory Committee on Dangerous Pathogens TSE Risk Assessment Subgroup “Position statement on occurrence of vCJD and prevalence of infection in the UK population”. Available at: http://transparency.dh.gov.uk/2012/08/13/tse-risk-assessment-july-2012/, accessed 15 November 2011.
- BennettPDobraSARisk assessment for variant CJD in blood transfusion: A perspective from the UKCreutzfeldt-Jakob Disease: Managing the Risk of Transmission from Blood, Plasma and Tissues2006245285
- BennettPHareATownshendJAssessing the risk of vCJD transmission via surgery: Models for uncertainty and complexityJournal of the Operational Research Society2004562202213
- BishopMTPredicting susceptibility and incubation time of human-to-human transmission of vCJDThe Lancet Neurology20065539339810.1016/S1474-4422(06)70413-6
- BruceMETransmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agentNature1997389665049850110.1038/39057
- ClarkePGhaniACProjections of the future course of the primary vCJD epidemic in the UK: Inclusion of subclinical infection and the possibility of wider genetic susceptibilityJournal of the Royal Society, Interface/the Royal Society200522193110.1098/rsif.2004.0017
- CollingeJPrion diseases of humans and animals: Their causes and molecular basisAnnual Review of Neuroscience200124151955010.1146/annurev.neuro.24.1.519
- CollingeJKuru in the 21st Century—An acquired human prion disease with very long incubation periodsThe Lancet200636795282068207410.1016/S0140-6736(06)68930-7
- d'AignauxJNHThe incubation period of KuruEpidemiology200213440240810.1097/00001648-200207000-00007
- Department of Health (2006). Exclusion of blood component recipients from donation: The impact on potential vCJD transmission risks. 1 July, http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4136942, accessed 11 February 2013.
- Department of Health (2009). Mapping out the consequences of screening blood donations for PrPSc, http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_094804, accessed 11 February 2013.
- Department of Health (2011). Blood-borne transmission of vCJD: Re-examination of scenarios, http://www.dh.gov.uk/health/2011/09/vcjd-scenarios/, accessed 11 February 2013.
- Det Norske Veritas Consulting (2004). Risk of infection from variant CJD in blood. Available at: http://ia201119.eu.archive.org/tna/20061004085342/dnv.com/consulting/news/riskofinfectionfromvariantcjdinblood.asp, accessed 18 July 2011.
- DoddRYPrions and precautions: Be careful for what you askTransfusion201050595695810.1111/j.1537-2995.2010.02638.x
- GarskeTGhaniACUncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UKPloS One2010512e1562610.1371/journal.pone.0015626
- GhaniACFergusonNMDonnellyCAHagenaarsTJAndersonRMEpidemiological determinants of the pattern and magnitude of the vCJD epidemic in Great BritainProceedings of the Royal Society of London. Series B: Biological Sciences199826514132443245210.1098/rspb.1998.0596
- GhaniACFergusonNMDonnellyCAAndersonRMPredicted vCJD mortality in Great BritainNature2000406679658358410.1038/35020688
- GregoriLEffectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from bloodLancet2004364943352953110.1016/S0140-6736(04)16812-8
- Gregori L, Yang H and Anderson S (2011). Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion, http://onlinelibrary.wiley.com/doi/10.1111/j.1537-2995.2011.03199.x/abstract, accessed 11 February 2013.
- HeadMWYullHMRitchieDLBishopMTIronsideJWPathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt–Jakob disease transmissionNeuropathology and Applied Neurobiology200935443343610.1111/j.1365-2990.2009.01025.x
- Health Protection Agency (2011). Interim data from the current national survey of abnormal prion prevalence in archived appendix specimens. September 2011, http://www.hpa.org.uk/hpr/archives/2011/news3611.htm#cjd.
- HewittPELlewelynCAMackenzieJWillRGCreutzfeldt–Jakob disease and blood transfusion: Results of the UK transfusion medicine epidemiological review studyVox Sanguinis200691322123010.1111/j.1423-0410.2006.00833.x
- HillAFThe same prion strain causes vCJD and BSENature1997389665044845010.1038/38925
- HiltonDAPrevalence of lymphoreticular prion protein accumulation in UK tissue samplesThe Journal of Pathology2004203373373910.1002/path.1580
- HoustonFPrion diseases are efficiently transmitted by blood transfusion in sheepBlood2008112124739474510.1182/blood-2008-04-152520
- IronsideJWVariant Creutzfeldt-Jakob disease: Prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence studyBritish Medical Journal200633275511186118810.1136/bmj.38804.511644.55
- KaskiDVariant CJD in an individual heterozygous for PRNP codon 129Lancet20093749707212810.1016/S0140-6736(09)61568-3
- KnightRThe risk of transmitting prion disease by blood or plasma productsTransfusion and Apheresis Science201043338739110.1016/j.transci.2010.09.003
- LefrèreJ-JHewittPFrom mad cows to sensible blood transfusion: The risk of prion transmission by labile blood components in the United Kingdom and in FranceTransfusion200949479781210.1111/j.1537-2995.2008.02044.x
- LlewelynCAPossible transmission of variant Creutzfeldt-Jakob disease by blood transfusionLancet2004363940741742110.1016/S0140-6736(04)15486-X
- PedenAVariant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophiliaHaemophilia201016229630410.1111/j.1365-2516.2009.02181.x
- PedenAHHeadMWDianeLRJeanneEBJamesWIPreclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patientThe Lancet2004364943352752910.1016/S0140-6736(04)16811-6
- StevensonMDOakleyJEChickSEChalkidouKThe cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humansJournal of the Operational Research Society200960450651810.1057/palgrave.jors.2602580
- UK NCJDRSU and UK Blood Services (2011). Transfusion medicine epidemiology review, http://www.cjd.ed.ac.uk/TMER/fate.htm, accessed 14 April 2011.
- WallisJPStrategies to reduce transfusion acquired vCJDTransfusion Medicine20112111610.1111/j.1365-3148.2010.01047.x
- WallisJPWellsAWMatthewsJNChapmanCELong-term survival after blood transfusion: A population based study in the North of EnglandTransfusion20044471025103210.1111/j.1537-2995.2004.03400.x
- WatkinsNADobraSABennettPCairnsJTurnerMLThe management of blood safety in the presence of uncertain risk: A United Kingdom perspectiveTransfusion Medicine Reviews201226323825110.1016/j.tmrv.2011.09.003
- WellsAWThe EASTR study: Indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood ServiceTransfusion Medicine200919631532810.1111/j.1365-3148.2009.00933.x
- WillBVariant CJD: Where has it gone, or has it?Practical Neurology201010525025110.1136/jnnp.2010.223693
- WroeSJClinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case reportLancet200636895522061206710.1016/S0140-6736(06)69835-8